Prime Medicine CSO Jeremy Duffield steps down effective July 15, 2025; retains as consultant through Mar 2026

Prime Medicine, Inc.

Jeremy Duffield, M.D., Ph.D., FRCP, resigns as Chief Scientific Officer effective July 15, 2025.
Company to enter Separation Agreement providing severance per his 2022 employment agreement.
Duffield retained as consultant from July 15, 2025 through March 31, 2026.
All outstanding equity awards continue vesting during the Advisory Period.
No successor named in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.